Takeda

We follow the science, to unlock innovation and pursue sustainable answers. We are guided by our commitment to patients, our people and the planet. Our vision is to deliver life-transforming treatments to those in need. We are steadfast in our purpose for better health for people and a brighter future for the world.

Meet Caroline Slomski, Global Head of Talent Acquisition for Global Manufacturing & Supply and Global Quality (GMS/GQ.) Caroline is a vital member of our team, driving success through strategic decision-making, mentoring and encouraging a positive culture. Alongside her team, Caroline is responsible for developing and executing recruitment, attraction and employer branding strategies, with the purpose of attracting global talent from diverse backgrounds. Caroline's approach to aligning her team with our goals is rooted in our values of Patient-Trust-Reputation-Business, ensuring every action supports our purpose. Learn more about Caroline’s career story: https://lnkd.in/e_24rbyG #InternationalMentoringDay #MakeHistoryChangeFutures #TeamTakeda

We’re proud to announce that we've been recognized as a Global Top Employer by the Top Employers Institute in 24 countries and three regions! Earning this recognition for the eighth year in a row validates our approach to creating an exceptional people experience through our global focus on ethics, integrity, purpose and values, enabling us to excel globally as one of just 17 companies worldwide to receive this honor. Be part of a team that’s committed to well-being while discovering and delivering life-transforming treatments worldwide—explore open roles today: https://lnkd.in/ezJmsdjY #TopEmployer2025 #TopEmployers2025 #MakeHistoryChangeFutures #TeamTakeda #LifeAtTakeda

Genetics plays a key role in immune-mediated inflammatory diseases. Differences in the TYK2 gene can influence an individual’s risk of developing conditions like #psoriasis and #PsoriaticArthritis. We’re committed to advancing research to deepen our understanding of the factors driving these diseases.

Our global network of ICCs is the digital heart of Takeda. By fostering new ideas and streamlining processes, they enhance efficiency, accelerate time-to-market, and ensure we continue meeting patients’ needs with agility and purpose. We are thrilled to announce the launch of our flagship Innovation Capability Centre (ICC)—our first in Asia— located in Bengaluru, India. It is a significant step forward in advancing healthcare through cutting-edge digital solutions. Today's milestone reflects our commitment to building a future-ready organization by leveraging technologies such as AI, generative AI, and robotics. The journey has just begun, and we eagerly anticipate what’s ahead as we continue shaping the future of healthcare. #TeamTakeda #ICCIndia #DigitalTransformationInHealthcare #InnovationCapabilityCentre

For years, they’ve seen the impact #dengue can have on patients. Hear from two physicians in Brazil on the local impact of the disease and how we can work to help reduce the burden. https://lnkd.in/eMF5g_dU #OurStories

Get a behind-the-scenes look at what drives Global Business Development (BD) Officer Marcello Agosti, how values play a role in BD and what sort of deals Takeda is currently seeking. As industry leaders and investors gather this week for the J.P. Morgan Healthcare Conference, read the full story at https://lnkd.in/eWwQxatx #OurStories #JPM25

#InflammatoryBowelDisease (IBD) is a chronic immune‐mediated disease characterized by inflammation of the gastrointestinal tract. Living with IBD is more than just “stomach trouble.” It’s a daily battle with inflammation, pain, anxiety and a myriad of other symptoms. Let’s work together to build a healthier future for the #IBDCommunity with a multidisciplinary approach to care: https://lnkd.in/etaf6N6y

Save the date and join the Dengue Academy Masterclass Series between 5th February - 27th May 2025. Register now for free at https://lnkd.in/daenWe4n #dengueacademy #denguemasterclass #dengueprevention This non-promotional educational series is organized and funded by Takeda Pharmaceuticals International AG, including the payment of external speakers as consultants. Events are intended for a professional medical and scientific audience outside of the US and UK and not for members of the general public.

Discover how the orexin pathway contributes to narcolepsy type 1 (NT1) – a chronic neurologic disease characterized by excessive daytime sleepiness. There is ongoing research to advance our understanding of this pathway. Learn more about NT1 and the science of orexin by watching our 3-minute video: https://lnkd.in/e-HRjCtC